Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu, China.
Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu, China.
Respiration. 2020;99(12):1109-1121. doi: 10.1159/000510793. Epub 2020 Dec 3.
Reducing asthma exacerbations is a major target of current clinical guidelines, but identifying features of exacerbation-prone asthma (EPA) using multidimensional assessment (MDA) is lacking.
To systemically explore the clinical and inflammatory features of adults with EPA in a Chinese population.
We designed a cross-sectional study using the Severe Asthma Web-based Database from the Australasian Severe Asthma Network (ASAN). Eligible Chinese adults with asthma (n = 546) were assessed using MDA. We stratified patients based on exacerbation frequency: none, few (1 or 2), and exacerbation prone (≥3). Univariate and multivariable negative binomial regression analyses were performed to investigate features associated with the frequency of exacerbations.
Of 546 participants, 61.9% had no exacerbations (n = 338), 29.6% had few exacerbations (n = 162), and 8.4% were exacerbation prone (n = 46) within the preceding year. EPA patients were characterized by elevated blood and sputum eosinophils but less atopy, with more controller therapies but worse asthma control and quality of life (all p < 0.05). In multivariable models, blood and sputum eosinophils (adjusted rate ratio = 2.23, 95% confidence interval = [1.26, 3.84] and 1.67 [1.27, 2.21], respectively), FEV1 (0.90 [0.84, 0.96]), bronchodilator responsiveness (1.16 [1.05, 1.27]), COPD (2.22 [1.41, 3.51]), bronchiectasis (2.87 [1.69, 4.89]), anxiety (2.56 [1.10, 5.95]), and depression (1.94 [1.20, 3.13]) were found. Further, upper respiratory tract infection (1.83 [1.32, 2.54]) and food allergy (1.67 [1.23, 2.25]) were at high risk of asthma symptom triggers.
EPA is a clinically recognizable phenotype associated with several recognizable traits that could be addressed by targeted treatment.
降低哮喘加重是当前临床指南的主要目标,但使用多维评估(MDA)识别易发生哮喘加重(EPA)的特征尚缺乏研究。
系统探索中国人群中 EPA 成人患者的临床和炎症特征。
我们使用澳大利亚严重哮喘网络(ASAN)的严重哮喘网络数据库进行了一项横断面研究。对符合条件的 546 名中国哮喘患者(n=546)进行 MDA 评估。我们根据发作频率对患者进行分层:无发作(n=338)、发作次数少(1 或 2 次)(n=162)和易发作(≥3 次)(n=46)。采用单变量和多变量负二项回归分析来探讨与发作频率相关的特征。
在 546 名参与者中,无发作(n=338)、发作次数少(n=162)和易发作(n=46)的患者分别占 61.9%、29.6%和 8.4%。EPA 患者的特点是血液和痰中嗜酸性粒细胞升高,但变应原较少,使用更多的控制器治疗,但哮喘控制和生活质量较差(均 P<0.05)。在多变量模型中,血液和痰中嗜酸性粒细胞(调整后比值比为 2.23,95%置信区间为[1.26,3.84]和 1.67 [1.27,2.21])、FEV1(0.90 [0.84,0.96])、支气管扩张剂反应性(1.16 [1.05,1.27])、COPD(2.22 [1.41,3.51])、支气管扩张症(2.87 [1.69,4.89])、焦虑(2.56 [1.10,5.95])和抑郁(1.94 [1.20,3.13])。此外,上呼吸道感染(1.83 [1.32,2.54])和食物过敏(1.67 [1.23,2.25])是哮喘症状触发的高危因素。
EPA 是一种临床可识别的表型,与几种可识别的特征相关,这些特征可通过针对性治疗来解决。